DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016" report to their offering.
The Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 report provides details of the latest option and evaluation agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of option and evaluation agreements from 2010 to 2016.
There are two major forms of deal term that allow a party to a deal to secure rights to an asset subject to a future event namely, option and evaluation.
Evaluation agreements allow a party to the deal to obtain rights to a technology or compound, subject to a period of time to evaluate the quality, scope and applicability of the technology to its intended endpoint. Normally the technology is at an early stage and/or unproven and the partnering company wishes to assess the technology as part of the due diligence process in advance of signing a long term licensing agreement.
Evaluation agreements have been a mainstay of technology licensing from the earliest days.
Key Topics Covered:
2 Trends in option and evaluation dealmaking
3 Overview of option and evaluation deal structure
4 Leading option and evaluation deals
5 Top 50 most active option and evaluation dealmakers
6 Option and evaluation contracts directory
- Aspen Pharmacare
- Baxter International
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- Endo Pharmaceuticals
- Forest Laboratories
- Gilead Sciences
- Johnson & Johnson
- Kyowa Hakko Kirin
- Merck & Co
- Merck KGaA
- Mitsubishi Tanabe
- Novo Nordisk
For more information about this report visit http://www.researchandmarkets.com/research/fs3rz3/global_option_and